Rezolute (RZLT) Projected to Post Quarterly Earnings on Wednesday

Rezolute (NASDAQ:RZLT) will likely be releasing its Q3 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Rezolute to post earnings of ($0.22) per share for the quarter.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Stock Performance

Shares of RZLT stock opened at $3.57 on Monday. Rezolute has a 1 year low of $2.22 and a 1 year high of $6.19. The stock has a market cap of $216.11 million, a PE ratio of -2.93 and a beta of 1.01. The business’s fifty day moving average is $3.24 and its 200-day moving average is $4.29.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on RZLT. Guggenheim reiterated a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Monday, April 28th. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Wedbush restated an “outperform” rating and issued a $12.00 target price on shares of Rezolute in a report on Wednesday, May 14th. Finally, JMP Securities lifted their target price on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.14.

Insider Transactions at Rezolute

In other Rezolute news, CEO Nevan C. Elam bought 12,302 shares of the firm’s stock in a transaction dated Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the transaction, the chief executive officer now directly owns 224,119 shares in the company, valued at approximately $638,739.15. This represents a 5.81% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wladimir Hogenhuis bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $4.70 per share, with a total value of $47,000.00. Following the transaction, the director now owns 77,267 shares of the company’s stock, valued at $363,154.90. This trade represents a 14.87% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 39,060 shares of company stock valued at $130,694 over the last quarter. Company insiders own 18.39% of the company’s stock.

Institutional Trading of Rezolute

An institutional investor recently bought a new position in Rezolute stock. Goldman Sachs Group Inc. bought a new position in Rezolute, Inc. (NASDAQ:RZLT) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 236,209 shares of the company’s stock, valued at approximately $685,000. Goldman Sachs Group Inc. owned 0.39% of Rezolute as of its most recent SEC filing. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.